Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
Pharma & Biotech
Pharma & Biotech
Why Oragenics, Inc.’ ONP-002 Phase IIa progress could redefine concussion treatment pathways
Can ONP-002 become the first approved concussion drug? Explore Oragenics’ Phase IIa progress and what it means for mTBI treatment.
Pharma & Biotech
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.